Skip to main content
Top

Open Access 06-11-2024 | Diabetic Retinopathy | COMMENTARY

Patient and Physician Perspectives of Diabetic Retinopathy and Diabetic Macular Edema Diagnosis, Treatment and Progression: A Podcast Article

Authors: Daniel Newman, Bernadette Warren, Randall Barker, Charles C. Wykoff, Stela Vujosevic

Published in: Ophthalmology and Therapy

Login to get access

Abstract

Diabetic retinopathy (DR) is one of the leading causes of vision loss among people of working age. However, people with diabetes are often unaware of the importance of DR screening for preserving vision, highlighting the importance of patient education about DR and DR-related ocular and systemic comorbidities. In this podcast, three patients with different stages of DR and two ophthalmologists exchanged their views on diagnosis, treatment, and progression of DR and diabetic macular edema. The discussion revealed that DR affects not only the physical aspects of patients’ lives but also their mental wellbeing. The challenges of a DR diagnosis can be compounded by communication gaps that exist between patients, physicians, and the pharmaceutical industry. Development of new therapies is currently informed mainly by physician perspectives. However, the large burden of current treatments calls for new therapeutic approaches that meet patients’ needs better. The preferred method of treatment administration can differ from patient to patient and the choices between treatments that necessitate repeated visits, monitoring, and at-home care must be discussed. As such, going forward it is crucial to consider both the physician and patient perspectives in shaping the clinical landscape of DR.
Literature
1.
go back to reference Alam S, Hasan MK, Neaz S, Hussain N, Hossain MF, Rahman T. Diabetes mellitus: insights from epidemiology, biochemistry, risk factors, diagnosis. Complic Compr Manag Diabetol. 2021;2:36–50. Alam S, Hasan MK, Neaz S, Hussain N, Hossain MF, Rahman T. Diabetes mellitus: insights from epidemiology, biochemistry, risk factors, diagnosis. Complic Compr Manag Diabetol. 2021;2:36–50.
2.
go back to reference Sinclair SH, Schwartz SS. Diabetic retinopathy—an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes. Front Endocrinol (Lausanne). 2019;10:843. Sinclair SH, Schwartz SS. Diabetic retinopathy—an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes. Front Endocrinol (Lausanne). 2019;10:843.
4.
go back to reference Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608–22.CrossRefPubMed Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608–22.CrossRefPubMed
5.
go back to reference Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.CrossRefPubMed Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.CrossRefPubMed
6.
go back to reference Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107:75–83.PubMedPubMedCentral Kollias AN, Ulbig MW. Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107:75–83.PubMedPubMedCentral
7.
go back to reference Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. 2020;34:1–51.CrossRefPubMedPubMedCentral Amoaku WM, Ghanchi F, Bailey C, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. 2020;34:1–51.CrossRefPubMedPubMedCentral
8.
go back to reference Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis Res. 2017;139:7–14.CrossRefPubMed Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis Res. 2017;139:7–14.CrossRefPubMed
9.
go back to reference Harris NR, Leskova W, Kaur G, Eshaq RS, Carter PR. Blood flow distribution and the endothelial surface layer in the diabetic retina. Biorheology. 2019;56:181–9.CrossRefPubMedPubMedCentral Harris NR, Leskova W, Kaur G, Eshaq RS, Carter PR. Blood flow distribution and the endothelial surface layer in the diabetic retina. Biorheology. 2019;56:181–9.CrossRefPubMedPubMedCentral
10.
go back to reference Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.CrossRefPubMed Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.CrossRefPubMed
11.
go back to reference Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic retinopathy: an overview of treatments. Indian J Endocrinol Metab. 2022;26:111–8.CrossRefPubMedPubMedCentral Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic retinopathy: an overview of treatments. Indian J Endocrinol Metab. 2022;26:111–8.CrossRefPubMedPubMedCentral
12.
go back to reference Hristova E, Koseva D, Zlatarova Z, Dokova K. Diabetic retinopathy screening and registration in Europe—narrative review. Healthcare (Basel). 2021;9:745. Hristova E, Koseva D, Zlatarova Z, Dokova K. Diabetic retinopathy screening and registration in Europe—narrative review. Healthcare (Basel). 2021;9:745.
13.
go back to reference Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–34.CrossRefPubMed Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–34.CrossRefPubMed
14.
go back to reference Fung TH, Patel B, Wilmot EG, Amoaku WM. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022;22:112–6.CrossRefPubMed Fung TH, Patel B, Wilmot EG, Amoaku WM. Diabetic retinopathy for the non-ophthalmologist. Clin Med (Lond). 2022;22:112–6.CrossRefPubMed
17.
go back to reference Laatikainen L, Ojamo M, Rudanko SL, et al. Improving visual prognosis of the diabetic patients during the past 30 years based on the data of the Finnish Register of Visual Impairment. Acta Ophthalmol. 2016;94:226–31.CrossRefPubMed Laatikainen L, Ojamo M, Rudanko SL, et al. Improving visual prognosis of the diabetic patients during the past 30 years based on the data of the Finnish Register of Visual Impairment. Acta Ophthalmol. 2016;94:226–31.CrossRefPubMed
18.
go back to reference Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000;78:374–85.CrossRefPubMed Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000;78:374–85.CrossRefPubMed
19.
go back to reference Jingi AM, Tankeu AT, Ateba NA, Noubiap JJ. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017;17:63.CrossRefPubMedPubMedCentral Jingi AM, Tankeu AT, Ateba NA, Noubiap JJ. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017;17:63.CrossRefPubMedPubMedCentral
20.
go back to reference Rehman I, Hazhirkarzar B, Patel BC. Anatomy, head and neck, eye. StatPearls [Internet]. Treasure Island (FL): StatPearls; 2023. Rehman I, Hazhirkarzar B, Patel BC. Anatomy, head and neck, eye. StatPearls [Internet]. Treasure Island (FL): StatPearls; 2023.
21.
go back to reference Bressler SB, Scanlon PH, Pearce E. Why is continued vision loss still a problem in some patients with diabetic retinopathy, despite treatment? JAMA Ophthalmol. 2022;140:308–9.CrossRefPubMed Bressler SB, Scanlon PH, Pearce E. Why is continued vision loss still a problem in some patients with diabetic retinopathy, despite treatment? JAMA Ophthalmol. 2022;140:308–9.CrossRefPubMed
22.
go back to reference Piyasena MMPN, Murthy GVS, Yip JLY, et al. Systematic review on barriers and enablers for access to diabetic retinopathy screening services in different income settings. PLoS ONE. 2019;14:e0198979.CrossRefPubMedPubMedCentral Piyasena MMPN, Murthy GVS, Yip JLY, et al. Systematic review on barriers and enablers for access to diabetic retinopathy screening services in different income settings. PLoS ONE. 2019;14:e0198979.CrossRefPubMedPubMedCentral
23.
go back to reference Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27:249–56.CrossRefPubMed Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27:249–56.CrossRefPubMed
24.
go back to reference Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020;8:337–47.CrossRefPubMed Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020;8:337–47.CrossRefPubMed
25.
go back to reference Avidor D, Loewenstein A, Waisbourd M, Nutman A. Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. Cost Eff Resour Alloc. 2020;18:16.CrossRefPubMedPubMedCentral Avidor D, Loewenstein A, Waisbourd M, Nutman A. Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. Cost Eff Resour Alloc. 2020;18:16.CrossRefPubMedPubMedCentral
26.
go back to reference Prothero L, Lawrenson JG, Cartwright M, et al. Barriers and enablers to diabetic eye screening attendance: an interview study with young adults with type 1 diabetes. Diabet Med. 2022;39:e14751.CrossRefPubMed Prothero L, Lawrenson JG, Cartwright M, et al. Barriers and enablers to diabetic eye screening attendance: an interview study with young adults with type 1 diabetes. Diabet Med. 2022;39:e14751.CrossRefPubMed
27.
go back to reference Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:168–73.CrossRefPubMedPubMedCentral Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132:168–73.CrossRefPubMedPubMedCentral
28.
go back to reference Woodmansey C, McGovern AP, McCullough KA, et al. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): a retrospective cohort study. Diabetes Care. 2017;40:1486–93.CrossRefPubMed Woodmansey C, McGovern AP, McCullough KA, et al. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): a retrospective cohort study. Diabetes Care. 2017;40:1486–93.CrossRefPubMed
29.
go back to reference Fairless E, Nwanyanwu K. Barriers to and facilitators of diabetic retinopathy screening utilization in a high-risk population. J Racial Ethn Health Dispar. 2019;6:1244–9.CrossRef Fairless E, Nwanyanwu K. Barriers to and facilitators of diabetic retinopathy screening utilization in a high-risk population. J Racial Ethn Health Dispar. 2019;6:1244–9.CrossRef
30.
go back to reference Saxena S, Jalali S, Meredith TA, Holekamp NM, Kumar D. Management of diabetic retinopathy. Indian J Ophthalmol. 2000;48:321–30.PubMed Saxena S, Jalali S, Meredith TA, Holekamp NM, Kumar D. Management of diabetic retinopathy. Indian J Ophthalmol. 2000;48:321–30.PubMed
31.
go back to reference Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10:Cd007419. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10:Cd007419.
32.
go back to reference Whitescarver TD, Hobbs SD, Wade CI, et al. A history of anti-VEGF inhibitors in the ophthalmic literature: a bibliographic review. J Vitreoretin Dis. 2021;5:304–12.CrossRefPubMed Whitescarver TD, Hobbs SD, Wade CI, et al. A history of anti-VEGF inhibitors in the ophthalmic literature: a bibliographic review. J Vitreoretin Dis. 2021;5:304–12.CrossRefPubMed
33.
go back to reference Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol (Lausanne). 2022;13:1077669.CrossRefPubMed Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol (Lausanne). 2022;13:1077669.CrossRefPubMed
34.
go back to reference Yonekawa Y, Modi YS, Kim LA, Skondra D, Kim JE, Wykoff CC. American Society of Retina Specialists clinical practice guidelines on the management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema. J Vitreoretin Dis. 2020;4:125–35.CrossRefPubMedPubMedCentral Yonekawa Y, Modi YS, Kim LA, Skondra D, Kim JE, Wykoff CC. American Society of Retina Specialists clinical practice guidelines on the management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema. J Vitreoretin Dis. 2020;4:125–35.CrossRefPubMedPubMedCentral
35.
go back to reference Nissen TPH, Vorum H, Aasbjerg K. Biologic therapy and treatment options in diabetic retinopathy with diabetic macular edema. Curr Drug Saf. 2021;16:17–31.CrossRefPubMed Nissen TPH, Vorum H, Aasbjerg K. Biologic therapy and treatment options in diabetic retinopathy with diabetic macular edema. Curr Drug Saf. 2021;16:17–31.CrossRefPubMed
36.
go back to reference Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open. 2017;7:e017902.CrossRefPubMedPubMedCentral Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary care physician consultation time: a systematic review of 67 countries. BMJ Open. 2017;7:e017902.CrossRefPubMedPubMedCentral
37.
go back to reference Sun WJ, An XD, Zhang YH, et al. The ideal treatment timing for diabetic retinopathy: the molecular pathological mechanisms underlying early-stage diabetic retinopathy are a matter of concern. Front Endocrinol (Lausanne). 2023;14:1270145.CrossRefPubMed Sun WJ, An XD, Zhang YH, et al. The ideal treatment timing for diabetic retinopathy: the molecular pathological mechanisms underlying early-stage diabetic retinopathy are a matter of concern. Front Endocrinol (Lausanne). 2023;14:1270145.CrossRefPubMed
38.
go back to reference Hoffmann-La Roche. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION): NCT04503551. Accessed 9 Aug 2024. Hoffmann-La Roche. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION): NCT04503551. Accessed 9 Aug 2024.
39.
go back to reference Jaeb Center for Health Research. Fenofibrate for prevention of DR worsening (Protocol AF): NCT04661358. Accessed 9 Aug 2024. Jaeb Center for Health Research. Fenofibrate for prevention of DR worsening (Protocol AF): NCT04661358. Accessed 9 Aug 2024.
40.
go back to reference BCN Peptides. Trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy (EUROCONDOR): NCT01726075. Accessed 9 Aug 2024. BCN Peptides. Trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy (EUROCONDOR): NCT01726075. Accessed 9 Aug 2024.
Metadata
Title
Patient and Physician Perspectives of Diabetic Retinopathy and Diabetic Macular Edema Diagnosis, Treatment and Progression: A Podcast Article
Authors
Daniel Newman
Bernadette Warren
Randall Barker
Charles C. Wykoff
Stela Vujosevic
Publication date
06-11-2024
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-024-01053-3

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more